Nelarabine Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 5 mg/mL
Reference Brands: Arranon (USA)
Category:
Oncology Cancer Care
Nelarabine is available in Injection
and strengths such as 5 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Nelarabine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Nelarabine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Nelarabine injection is an antineoplastic medication used in the treatment of specific types of cancer, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It is generally prescribed for patients whose disease has not responded to, or has relapsed after, treatment with at least two other cancer therapies. Nelarabine is administered by intravenous injection under strict medical supervision, usually in specialized oncology settings.
Nelarabine belongs to a group of medicines known as antineoplastics and works by interfering with the growth and replication of cancer cells. By disrupting cellular processes essential for cancer cell survival, nelarabine leads to the destruction of malignant T-cells. However, because this medicine can also affect normal, rapidly dividing cells in the body, patients may experience side effects during treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing